# Gilead Sciences, Inc. (GILD) — Q4-2025 Earnings Results

**Report date:** 2026-02-10 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2025

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down 2.93%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.86 | N/A | +1.92% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future developments. They emphasized their commitment to innovation and addressing market needs.

**Key quotes:**

> Management highlighted ongoing efforts to enhance product pipeline.

> They expressed confidence in long-term growth despite current market challenges.

### Guidance Changes

No forward guidance was provided during this earnings call.

### What It Means

Gilead Sciences reported a slight earnings beat on EPS, but the stock fell by nearly 3% following the announcement. Investors may be concerned about the lack of revenue data and forward guidance, which could indicate uncertainty about future performance. The stock reaction suggests that market sentiment remains cautious despite the positive EPS surprise.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2025_